Baseline patient (DMARD-IR population) demographics and characteristics, stratified by response by Week 8.
| Placebo + DMARD n = 1010 | TCZ 4 mg/kg + DMARD n = 612 | TCZ 8 mg/kg + DMARD n = 1406 | ||||
|---|---|---|---|---|---|---|
| ≥ 50% Improvement in SJC66 by Week 8 | Yes, n = 386 | No, n = 624 | Yes, n = 328 | No, n = 284 | Yes, n = 754 | No, n = 652 |
| Age, yrs, mean (SD) | 51.6 (12.5) | 52.4 (12.8) | 51.9 (12.8) | 50.9 (12.5) | 52.8 (12.5) | 52.8 (12.0) |
| Sex, n (%) | ||||||
| Female | 313 (81.1) | 520 (83.3) | 266 (81.1) | 245 (86.3) | 610 (80.9) | 544 (83.4) |
| Male | 73 (18.9) | 104 (16.7) | 62 (18.9) | 39 (13.7) | 144 (19.1) | 108 (16.6) |
| Race, n (%) | ||||||
| American Indian or Alaska Native | 36 (9.3) | 33 (5.3) | 28 (8.5) | 13 (4.6) | 65 (8.6) | 51 (7.8) |
| Asian | 25 (6.5) | 63 (10.1) | 19 (5.8) | 23 (8.1) | 70 (9.3) | 57 (8.7) |
| Black | 19 (4.9) | 25 (4.0) | 9 (2.7) | 15 (5.3) | 22 (2.9) | 37 (5.7) |
| Other | 45 (11.7) | 40 (6.4) | 37 (11.3) | 29 (10.2) | 55 (7.3) | 41 (6.3) |
| White | 261 (67.6) | 463 (74.2) | 235 (71.6) | 204 (71.8) | 542 (71.9) | 466 (71.5) |
| Baseline DAS28, mean (SD) | 6.5 (0.9) | 6.7 (1.0) | 6.5 (1.0) | 6.7 (0.9) | 6.6 (1.0) | 6.8 (1.0) |
| Oral corticosteroids at baseline, n (%) | 235 (60.9) | 378 (60.6) | 215 (65.5) | 177 (62.3) | 424 (56.2) | 355 (54.4) |
| Baseline RF-positive, n (%) | 287 (74.4) | 489 (78.4) | 266 (81.1) | 223 (78.5) | 617 (81.8) | 508 (77.9) |
| Previous DMARD/anti-TNF, n, median (range) | 1 (0–10) | 1 (0–8) | 1 (0–8) | 1 (0–8) | 1 (0–8) | 1 (0–9) |
| Duration of RA, yrs, mean (SD) | 8.8 (8.4) | 9.2 (8.4) | 8.9 (7.9) | 8.6 (7.6) | 9.1 (8.2) | 9.6 (8.8) |
| At Least Moderate RAPID3 response by Week 8 | Yes, n = 499 | No, n = 511 | Yes, n = 381 | No, n = 231 | Yes, n = 937 | No, n = 469 |
| Age, yrs, mean (SD) | 51.8 (12.7) | 52.4 (12.7) | 52.3 (12.6) | 50.0 (12.7) | 52.6 (12.5) | 53.3 (11.7) |
| Sex, n (%) | ||||||
| Female | 412 (82.6) | 421 (82.4) | 313 (82.2) | 198 (85.7) | 777 (82.9) | 377 (80.4) |
| Male | 87 (17.4) | 90 (17.6) | 68 (17.8) | 33 (14.3) | 160 (17.1) | 92 (19.6) |
| Race, n (%) | ||||||
| American Indian or Alaska Native | 37 (7.4) | 32 (6.3) | 15 (3.9) | 26 (11.3) | 79 (8.4) | 37 (7.9) |
| Asian | 40 (8.0) | 48 (9.4) | 26 (6.8) | 16 (6.9) | 88 (9.4) | 39 (8.3) |
| Black | 27 (5.4) | 17 (3.3) | 18 (4.7) | 6 (2.6) | 38 (4.1) | 21 (4.5) |
| Other | 32 (6.4) | 53 (10.4) | 34 (8.9) | 32 (13.9) | 47 (5.0) | 49 (10.4) |
| White | 363 (72.7) | 361 (70.6) | 288 (75.6) | 151 (65.4) | 685 (73.1) | 323 (68.9) |
| Baseline DAS28, mean (SD) | 6.7 (0.9) | 6.6 (1.0) | 6.6 (0.9) | 6.6 (0.9) | 6.7 (1.0) | 6.5 (1.1) |
| Oral corticosteroids at baseline, n (%) | 328 (65.7) | 285 (55.8) | 248 (65.1) | 144 (62.3) | 528 (56.4) | 251 (53.5) |
| Baseline RF-positive, n (%) | 380 (76.2) | 396 (77.5) | 315 (82.7) | 174 (75.3) | 771 (82.3) | 354 (75.5) |
| Previous nonbiologic DMARD/anti-TNF, n, median (range) | 1 (0–7) | 1 (0–10) | 1 (0–8) | 1 (0–6) | 1 (0–9) | 1 (0–8) |
| Duration of RA, yrs, mean (SD) | 8.6 (8.3) | 9.5 (8.5) | 9.0 (8.2) | 8.4 (7.0) | 9.1 (8.3) | 9.8 (8.8) |
DAS28: Disease Activity Score using 28 joints; DMARD: disease-modifying antirheumatic drug; DMARD-IR: DMARD inadequate response; RAPID3: Routine Assessment of Patient Index Data 3; RA: rheumatoid arthritis; SJC66: swollen joint count based on 66 joints; TCZ: tocilizumab; RF: rheumatoid factor; TNF: tumor necrosis factor.